

**Table S1.** Effects of ticagrelor combined with aspirin and ticagrelor combined with placebo on platelet reactivity evaluated with MEA-ADP, MEA-AA, and VASP in venous blood from baseline to 24 h and from 2 h to 24 h in 44 healthy male volunteers

	MEA-ADP (U)		MEA-AA (U)		VASP (PRI)	
	Ticagrelor + aspirin	Ticagrelor + placebo	Ticagrelor + aspirin	Ticagrelor + placebo	Ticagrelor + aspirin	Ticagrelor + placebo
Baseline	70 (63; 79)	67 (62; 74)	84.5 (78; 91)	83.5 (79; 94)	85 (82; 87.6)	85.6 (81.8; 87.1)
2 h	20 (16; 24)	24 (20; 27)	11 (7; 16)	60 (48; 72)	10.1 (4.9; 16)	12.1 (6.8; 18.2)
24 h	32.5 (26; 45)	31 (27; 55)	18.5 (13; 24)	74.5 (72; 86)	43.9 (31.4; 54.1)	46 (33.8; 63.5)
p-Value <sup>a</sup>	<0.0001	<0.0001	<0.0001	0.02	<0.0001	<0.0001
p-Value <sup>b</sup>	0.049		<0.0001		0.27	
Δmean <sup>a</sup>	-36.6 (-40.9; -32.4)	-30.6 (-34.9; -26.4)	-67.0 (-73.8; -60.3)	-9.4 (-16.1; -2.6)	-40.3 (-49.5; -31.2)	-33.2 (-42.4; -24.0)
Δmean <sup>b</sup>	-6.0		-57.7		-7.1	

	(-12.0; -0.02)		(-67.3; -48.1)		(-20.1; 5.9)	
p-Value <sup>c</sup>	<0.0001	<0.0001	0.01	<0.0001	<0.0001	<0.0001
p-Value <sup>d</sup>	0.85		0.002		0.33	
Δmean <sup>c</sup>	14.7 (8.7; 20.7)	15.5 (9.5; 21.6)	5.9 (1.4; 10.3)	16.3 (11.9; 20.8)	30.0 (20.8; 39.2)	36.4 (27.2; 45.6)
Δmean <sup>d</sup>	-0.8 (-9.3; 7.7)		-10.5 (-16.8; -4.1)		-6.4 (-19.4; 6.6)	

<sup>a</sup>From baseline to 24 h. <sup>b</sup>Differences between treatment groups in the interval from baseline to 24 h. <sup>c</sup>From 2 h to 24 h. <sup>d</sup>Differences between treatment groups in the interval from 2 h to 24 h. Values are given as median (quartiles) or mean difference (Δmean) (95% confidence interval) for multiple electrode aggregometry ADPtest (MEA-ADP), multiple electrode aggregometry ASPItest (MEA-AA), and vasodilator-stimulated phosphoprotein (VASP). U = units, PRI = platelet reactivity index.